Patents by Inventor Fiona Baker
Fiona Baker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240016456Abstract: Embodiments are directed to a non-transitory computer-readable storage medium comprising instructions that when executed cause processor circuitry to generate a longitudinal dataset of a set of features from tracked physical measurements of a user received from sensor circuitry, apply at least one machine learning model to the longitudinal dataset of the set of features to identify a pattern within the set of features indicative of a probability of the user being in a state of menopause, predict a current state of menopause for the user based on the identified pattern, and communicate a data message indicative of the current state of menopause for the user. In some embodiments, the set of features are compressed to pseudo-features and input to a first ML model using a second ML model.Type: ApplicationFiled: November 3, 2021Publication date: January 18, 2024Applicant: SRI InternationalInventors: Massimiliano de Zambotti, Fiona Baker, Andreas Tsiartas
-
Publication number: 20230329631Abstract: Example embodiments are directed systems including processing circuitry and memory circuitry to store a predictive data model indicative of different patterns and probabilities of a user transitioning from an awake state to a sleep state. The processing circuitry is to detect, using data indicative of a current psychophysiological state of the user, a pattern among the different patterns of the predictive data model that is indicative of a probability of the user transitioning from the awake state to the sleep state at a date and time, based on the detected pattern, select an intervention action predicted to increase the probability of the user transitioning to the sleep state at the date and time, and communicate a message indicative of the intervention action to the user.Type: ApplicationFiled: June 29, 2021Publication date: October 19, 2023Applicant: SRI InternationalInventors: Massimiliano de Zambotti, Fiona Baker, Devin Prouty, Ian Colrain, Bhaskar Ramamurthy, Glen W. McLaughlin
-
Publication number: 20230277106Abstract: Embodiments in accordance with the present disclosure are directed to systems, devices, and methods involving hot flash (HF) multi-sensor circuits. An example system includes a plurality of sensor circuits and processor circuitry. The sensor circuits obtain a plurality of sensor signals associated with the user. The processor circuitry extracts features from the plurality of sensor signals obtained by the plurality of sensor circuits, aligns the extracted features to a common time point, identifies a HF event for the user using a predictive data model indicative of probability of the HF event occurring for the user at a date and time and based on the aligned extracted features, and communicates a message indicative of the HF event to the user.Type: ApplicationFiled: August 6, 2021Publication date: September 7, 2023Applicant: SRI InternationalInventors: Massimiliano de Zambotti, Fiona Baker, David Smith, Andreas Tsiartas
-
Publication number: 20060217397Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: ApplicationFiled: November 2, 2005Publication date: September 28, 2006Inventors: Andrew Wolff, Fiona Baker, John Langridge
-
Publication number: 20060147521Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: ApplicationFiled: September 7, 2005Publication date: July 6, 2006Inventors: Andrew Wolff, Fiona Baker, John Langridge
-
Publication number: 20040097514Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: ApplicationFiled: July 7, 2003Publication date: May 20, 2004Inventors: Andrew A. Wolff, Fiona Baker, John Richard Langridge
-
Publication number: 20040029890Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/nL.Type: ApplicationFiled: July 7, 2003Publication date: February 12, 2004Applicant: CV Therapeutics, Inc.Inventors: Andrew A. Wolff, Fiona Baker, John Richard Langridge
-
Patent number: 6620814Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: GrantFiled: September 27, 2002Date of Patent: September 16, 2003Assignee: CV Therapeutics, Inc.Inventors: Andrew A. Wolff, Fiona Baker, John Langridge
-
Patent number: 6617328Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: GrantFiled: September 27, 2002Date of Patent: September 9, 2003Assignees: CV Therapeutics, Inc, Syntex (USA), LLCInventors: Andrew A. Wolff, Fiona Baker, John Langridge
-
Publication number: 20030100566Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: ApplicationFiled: September 27, 2002Publication date: May 29, 2003Applicant: CV Therapeutics, Inc.Inventors: Andrew A. Wolff, Fiona Baker, John Richard Langridge
-
Publication number: 20030099705Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: ApplicationFiled: September 27, 2002Publication date: May 29, 2003Applicant: CV Therapeutics, Inc.Inventors: Andrew A. Wolff, Fiona Baker, John Richard Langridge
-
Patent number: 6525057Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: GrantFiled: August 9, 2001Date of Patent: February 25, 2003Assignee: CV Therapeutics, Inc.Inventors: Andrew A. Wolff, Fiona Baker, John Langridge
-
Patent number: 6503911Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: GrantFiled: October 19, 2001Date of Patent: January 7, 2003Assignees: CV Therapeutics, Inc., Syntex USA, Inc.Inventors: Andrew A. Wolff, Fiona Baker, John Langridge
-
Publication number: 20020090396Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: ApplicationFiled: October 19, 2001Publication date: July 11, 2002Applicant: CV Therapeutics, Inc.Inventors: Andrew A. Wolff, Fiona Baker, John R. Langridge
-
Patent number: 6369062Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: GrantFiled: March 29, 2000Date of Patent: April 9, 2002Assignees: CV Therapeutics, Inc., Syntex (USA) Inc.Inventors: Andrew A. Wolff, Fiona Baker, John Langridge
-
Publication number: 20020004506Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: ApplicationFiled: August 9, 2001Publication date: January 10, 2002Applicant: CV Therapeutics, Inc.Inventors: Andrew A. Wolff, Fiona Baker, John R. Langridge
-
Patent number: 6303607Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: GrantFiled: May 27, 1999Date of Patent: October 16, 2001Assignee: CV Therapeutics, Inc.Inventors: Andrew A. Wolff, Fiona Baker, John Richard Langridge